Exparel is an analgesic drug owned by Pacira Pharms Inc. Composed of bupivacaine, it was first authorized for market use on October 28, 2011. The drug is available in the form of injectable, liposomal injections and holds 9 drug patents currently, none of which have expired.
Based on the patents held by Exparel, its generics are unlikely to be available until after January 22, 2041. The primary reason for this delay is the numerous patents protecting it, including those related to the manufacture of Bupivacaine multivesicular liposomes.
The major use of Exparel is for the treatment and management of pain. Its method of administration can vary, including via infiltration for local analgesia or through interscalene brachial plexus nerve block for regional analgesia. It is specifically designed to provide postsurgical pain management.
Exparel currently holds 9 patents, all of which are valid and protect it from generic competition until 2041. The majority of these patents are related to the manufacturing process of Bupivacaine multivesicular liposomes. Below are the details of the patent: